Publications by authors named "Andrew Judd"

Claim this Profile
B
BCL-X-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.
Andrew S Judd, Bhupinder Bawa, Wayne R Buck, Zhi-Fu Tao, Yingchun Li

Sci Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467.
Patrick B Brady, Bryan K Sorensen, Roberto M Risi, Michael L Curtin, Robert A Mantei, Andrew S Judd

J Org Chem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Junichiro Yuda, Christine Will, Darren C Phillips, Linu Abraham, Cory Alvey, Andrew S Judd

Commun Med (Lond)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioselective Bioreduction of Medicinally Relevant Nitrogen-Heteroaromatic Ketones.
Wen-Ju Bai, Michelle A Estrada, Jackson A Gartman, Andrew S Judd

ACS Med Chem Lett· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of a 50-gene next generation sequencing panel with post-centrifuge supernatant cytology fluid in non-small-cell lung cancer.
Marissa Tafoya, Andrew Judd, Kelsey Chiotti, Karen Dearen, Kassandra Jiron

Diagn Cytopathol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of A-1293102, a Potent and Selective BCL-X Inhibitor.
Zhi-Fu Tao, Xilu Wang, Jun Chen, Justin P Ingram, Sha Jin, Andrew S Judd

ACS Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X Inhibitor.
Le Wang, George A Doherty, Andrew S Judd, Zhi-Fu Tao, T Matthew Hansen

ACS Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer.
Gregory J Tsongalis, M Rabie Al Turkmani, Michael Suriawinata, Michael J Babcock, Kristi Mitchell, Andrew Judd

Am J Clin Pathol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Aspects of Bacterial Outer Membrane Protein Assembly.
Charles Calmettes, Andrew Judd, Trevor F Moraes

Adv Exp Med Biol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria.
Yogesh Hooda, Christine Chieh-Lin Lai, Andrew Judd, Carolyn M Buckwalter, Hyejin Esther Shin

Nat Microbiol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for the recruitment of glycogen synthase by glycogenin.
Elton Zeqiraj, Xiaojing Tang, Roger W Hunter, Mar García-Rocha, Andrew Judd

Proc Natl Acad Sci U S A· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.
Vince S C Yeh, David W A Beno, Sevan Brodjian, Michael E Brune, Steven C Cullen, Andrew S Judd

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents.
Andrew J King, Andrew S Judd, Andrew J Souers

Expert Opin Ther Pat· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.
Andrew S Judd, Andrew J Souers, Philip R Kym

Curr Top Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Gang Zhao, Andrew J Souers, Martin Voorbach, H Doug Falls, Brian Droz, Andrew S Judd

J Med Chem· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists.
Philip R Kym, Andrew S Judd, John K Lynch, Rajesh Iyengar, Anil Vasudevan

Curr Top Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concise construction of novel bridged bicyclic lactams by sequenced Ugi/RCM/Heck reactions.
Timothy P Ribelin, Andrew S Judd, Irini Akritopoulou-Zanze, Rodger F Henry, Jeffrey L Cross

Org Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators.
Gang Zhao, Rajesh R Iyengar, Andrew S Judd, Barbara Cool, William Chiou

Bioorg Med Chem Lett· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Andrew S Judd, Andrew J Souers, Dariusz Wodka, Gang Zhao, Mathew M Mulhern

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
Andrew J Souers, Rajesh R Iyengar, Andrew S Judd, David W A Beno, Ju Gao

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.
Rajesh R Iyengar, John K Lynch, Mathew M Mulhern, Andrew S Judd, Jennifer C Freeman

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Zhonghua Pei, Xiaofeng Li, Thomas W von Geldern, David J Madar, Kenton Longenecker, Andrew S Judd

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.
John K Lynch, Jennifer C Freeman, Andrew S Judd, Rajesh Iyengar, Mathew Mulhern

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
Philip R Kym, Andrew J Souers, Thomas J Campbell, John K Lynch, Andrew S Judd

J Med Chem· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.
Philip R Kym, Rajesh Iyengar, Andrew J Souers, John K Lynch, Andrew S Judd

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis